Kiora Pharmaceuticals Inc (KPRX) Hedge Fund & Institutional Holdings (Q2 2026)

KPRX ranks #8180 out of 37503 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

KPRX is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

22 institutions disclose a position in KPRX, but none treat it as a major bet — even Scientech Research LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

Ken Griffin has added to its KPRX position for two straight quarters, increasing it by $261.0K to reach $305.1K today.

KPRX is down 0% today, but institutions show net buying of $2.1M this quarter — a divergence between today's price move and the underlying institutional flow.

KPRX reported a net loss of $11.0M over the trailing twelve months.

• Not yet profitable — net loss of $11.0M over the trailing twelve months
• Revenue declined 100.0% year over year
• Net income improved year over year, from -$12.0M to -$11.0M
• Operating cash flow was negative, using $10.0M in cash
• Current ratio of 5.99x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.50x equity — within a conventional range